| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
25,230,000 |
| Market
Cap: |
236.66(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.69 - $14.07 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Verastem is a late stage development biopharmaceutical company, with ongoing registration directed trials, focused on developing and commercializing medicines for patients battling cancer. Co.'s product candidates, VS-6766 and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors. VS-6766 is an orally available small molecule rapidly accelerated fibrosarcoma/ mitogen-activated protein kinase kinase clamp. Defactinib is an oral small molecule inhibitor of Focal Adhesion Kinase and proline-rich tyrosine kinase that is being evaluated as a potential combination therapy for various solid tumors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
10,939 |
21,833 |
25,311 |
170,875 |
| Total Sell Value |
$144,537 |
$258,319 |
$292,764 |
$394,058 |
| Total People Sold |
4 |
4 |
4 |
4 |
| Total Sell Transactions |
10 |
20 |
37 |
64 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Calkins Daniel |
Chief Financial Officer |
• – – |
2024-04-05 |
4 |
S |
$10.87 |
$65 |
D/D |
(6) |
8,535 |
|
19% |
|
| Calkins Daniel |
Chief Financial Officer |
• – – |
2024-03-25 |
4 |
S |
$12.02 |
$301 |
D/D |
(25) |
8,541 |
|
20% |
|
| Calkins Daniel |
Chief Financial Officer |
• – – |
2024-03-20 |
4 |
S |
$11.07 |
$609 |
D/D |
(55) |
8,566 |
|
22% |
|
| Gagnon Robert E. |
Director |
– • – |
2024-03-19 |
4 |
S |
$10.38 |
$1,349 |
D/D |
(130) |
27,391 |
|
19% |
|
| Paterson Dan |
President and CEO |
• • – |
2024-03-19 |
4 |
S |
$10.38 |
$1,889 |
D/D |
(182) |
86,490 |
|
19% |
|
| Stuglik Brian M |
Director |
– • – |
2024-03-19 |
4 |
S |
$10.38 |
$2,834 |
D/D |
(273) |
89,640 |
|
19% |
|
| Gagnon Robert E. |
Director |
– • – |
2024-03-18 |
4 |
S |
$10.71 |
$3,031 |
D/D |
(283) |
27,521 |
|
13% |
|
| Paterson Dan |
President and CEO |
• • – |
2024-03-18 |
4 |
S |
$10.71 |
$2,613 |
D/D |
(244) |
86,672 |
|
13% |
|
| Stuglik Brian M |
Director |
– • – |
2024-03-18 |
4 |
S |
$10.71 |
$5,751 |
D/D |
(537) |
89,913 |
|
13% |
|
| Gagnon Robert E. |
Director |
– • – |
2024-02-06 |
4 |
AS |
$13.70 |
$126,095 |
D/D |
(9,204) |
27,804 |
|
-33% |
|
| Gagnon Robert E. |
Director |
– • – |
2024-01-12 |
4 |
AS |
$10.95 |
$100,784 |
D/D |
(9,204) |
37,008 |
|
-15% |
|
| Calkins Daniel |
Chief Financial Officer |
• – – |
2024-01-05 |
4 |
S |
$8.50 |
$51 |
D/D |
(6) |
8,621 |
|
-9% |
|
| Calkins Daniel |
Chief Financial Officer |
• – – |
2023-12-26 |
4 |
S |
$8.08 |
$202 |
D/D |
(25) |
8,350 |
|
-15% |
|
| Calkins Daniel |
Chief Financial Officer |
• – – |
2023-12-20 |
4 |
S |
$7.93 |
$452 |
D/D |
(57) |
8,375 |
|
-19% |
|
| Stuglik Brian M |
Director |
– • – |
2023-12-19 |
4 |
S |
$7.73 |
$2,118 |
D/D |
(274) |
90,450 |
|
-15% |
|
| Gagnon Robert E. |
Director |
– • – |
2023-12-19 |
4 |
S |
$7.73 |
$1,005 |
D/D |
(130) |
46,212 |
|
-15% |
|
| Paterson Dan |
President and CEO |
• • – |
2023-12-19 |
4 |
S |
$7.73 |
$1,415 |
D/D |
(183) |
86,916 |
|
-15% |
|
| Stuglik Brian M |
Director |
– • – |
2023-12-18 |
4 |
S |
$7.64 |
$3,721 |
D/D |
(487) |
90,724 |
|
-18% |
|
| Gagnon Robert E. |
Director |
– • – |
2023-12-18 |
4 |
S |
$7.64 |
$2,170 |
D/D |
(284) |
46,342 |
|
-18% |
|
| Paterson Dan |
President and CEO |
• • – |
2023-12-18 |
4 |
S |
$7.64 |
$1,864 |
D/D |
(244) |
87,099 |
|
-18% |
|
| Calkins Daniel |
Vice President of Finance |
• – – |
2023-10-05 |
4 |
S |
$7.30 |
$37 |
D/D |
(5) |
8,432 |
|
-53% |
|
| Calkins Daniel |
Vice President of Finance |
• – – |
2023-09-25 |
4 |
S |
$9.40 |
$235 |
D/D |
(25) |
8,437 |
|
-31% |
|
| Calkins Daniel |
Vice President of Finance |
• – – |
2023-09-21 |
4 |
S |
$9.31 |
$2,160 |
D/D |
(232) |
8,462 |
|
-24% |
|
| Gagnon Robert E. |
Director |
– • – |
2023-09-19 |
4 |
S |
$9.84 |
$1,279 |
D/D |
(130) |
46,626 |
|
-30% |
|
| Stuglik Brian M |
Director |
– • – |
2023-09-19 |
4 |
S |
$9.84 |
$2,696 |
D/D |
(274) |
91,211 |
|
-30% |
|
168 Records found
|
|
Page 1 of 7 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.17 (1.79%) 
